Remove Resources Preclinical
article thumbnail

Deal value increased by 19.2 per cent in Jan 2024, compared to Jan 2023: GlobalData

Express Pharma

5-Jan-24 Bail Capital; EIR Pharmaceuticals LLC; Helena Laboratories Corp; Jetti Resources, LLC; Joe and Sandy Samberg Foundation; Satori Neuro; Steven & Alexandra Cohen Foundation Inc; True Ventures; Undisclosed; Unlikely Collaborators Foundation; Vine Ventures Lykos Therapeutics (US) 100.0 The post Deal value increased by 19.2

article thumbnail

Exicure and Bluejay sign hepatitis treatment development deal

Pharmaceutical Business Review

Specialising in virology and liver disease, Bluejay Therapeutics is advancing two preclinical programmes aimed at reducing HBsAg load and restoring antiviral immunity to develop a functional cure for chronic hepatitis B virus (CHBV) infection. Exicure has spent considerable resources to discover and develop cavrotolimod.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

InvisiShield and Gladstone partner to develop intranasal preventatives

Pharmaceutical Technology

Scientists at Gladstone Institutes will be responsible for carrying out preclinical studies to assess the efficacy and safety of the product. Under the partnership terms, InvisiShield will offer technical support, as well as funding to develop the intranasal preventatives.

Immunity 115
article thumbnail

HanAll Biopharma and Daewoong sign deal to develop Parkinson’s therapy

Pharmaceutical Technology

HanAll Biopharma and Daewoong Pharmaceutical will combine their resources and knowledge to develop NurrOn’s ATH-399A and other compounds targeting Nurr1 [nuclear receptor-related 1 protein] to treat neurodegenerative disorders. They will help to progress ATH-399A towards a Phase I trial.

article thumbnail

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734

PharmaShots

IMP1734 showed a high anti-tumor activity and a wide therapeutic window in the preclinical in vivo models Ref: prnewswire | Image: Impact Therapeutics Related News:- IMPACT Therapeutics’ IMP4297 and Temozolomide Receives the US FDA’s Orphan Drug Designation for Small Cell Lung Cancer PharmaShots!

40
article thumbnail

BullFrog AI, Sage Group partner to develop oncology assets

Pharma Leaders

This partnership will focus on exploring joint venture (JV) opportunities for advancing a Phase II ready asset and the preclinical prodrug asset of BullFrog AI. The Phase II ready asset targets glioblastoma, which is an aggressive form of brain cancer.

52
article thumbnail

BullFrog AI, Sage Group partner to develop oncology assets

Pharmaceutical Business Review

This partnership will focus on exploring joint venture (JV) opportunities for advancing a Phase II ready asset and the preclinical prodrug asset of BullFrog AI. The Phase II ready asset targets glioblastoma, which is an aggressive form of brain cancer.

52